Lord, Abbett & Co
CCXI

Lord, Abbett & Co’s ChemoCentryx, Inc. CCXI Stock Holding History

Lord, Abbett & Co’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-117,152
Closed -$6.05M – 667
2022
Q3 		$6.05M Sell
117,152
-63,133
-35% -$2.61M 0.02% 456
2022
Q2 		$4.47M Buy
+180,285
New +$3.97M 0.02% 504
2021
Q2 		– Sell
-565,911
Closed -$29M – 729
2021
Q1 		$29M Buy
565,911
+69,147
+14% +$4.16M 0.07% 359
2020
Q4 		$30.8M Sell
496,764
-47,632
-9% -$2.73M 0.08% 347
2020
Q3 		$29.8M Buy
544,396
+27,805
+5% +$1.5M 0.1% 304
2020
Q2 		$29.7M Sell
516,591
-168,678
-25% -$9.18M 0.1% 302
2020
Q1 		$27.5M Buy
685,269
+204,316
+42% +$8.68M 0.12% 262
2019
Q4 		$19M Buy
+480,953
New +$8.45M 0.06% 398

Other funds holding CCXI

HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Lord, Abbett & Co's CCXI Position: Q4 2022 in Review

Lord, Abbett & Co sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 117,152 shares — an estimated $6.05M sold.

Lord, Abbett & Co first reported a position in CCXI in Q4 2019 and held it in 8 quarters. The position peaked at $30.8M in Q4 2020. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.

  • Lord, Abbett & Co reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
  • Lord, Abbett & Co sold 117,152 ChemoCentryx, Inc. shares in Q4 2022, an estimated $6.05M.
  • Lord, Abbett & Co first reported a position in ChemoCentryx, Inc. in Q4 2019 and held it in 8 quarters.
  • Lord, Abbett & Co's ChemoCentryx, Inc. position peaked at $30.8M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.

Based on Lord, Abbett & Co's 13F filing for Q4 2022, filed 10 Feb 2023.